PH12021553180A1 - Inhibitors of human immunodeficiency virus replication - Google Patents

Inhibitors of human immunodeficiency virus replication

Info

Publication number
PH12021553180A1
PH12021553180A1 PH1/2021/553180A PH12021553180A PH12021553180A1 PH 12021553180 A1 PH12021553180 A1 PH 12021553180A1 PH 12021553180 A PH12021553180 A PH 12021553180A PH 12021553180 A1 PH12021553180 A1 PH 12021553180A1
Authority
PH
Philippines
Prior art keywords
immunodeficiency virus
human immunodeficiency
inhibitors
virus replication
hiv
Prior art date
Application number
PH1/2021/553180A
Other languages
English (en)
Inventor
Eric P Gillis
Christiana Iwuagwu
Original Assignee
Viiv Healthcare Uk No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Uk No 5 Ltd filed Critical Viiv Healthcare Uk No 5 Ltd
Publication of PH12021553180A1 publication Critical patent/PH12021553180A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH1/2021/553180A 2019-06-19 2020-06-17 Inhibitors of human immunodeficiency virus replication PH12021553180A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962863406P 2019-06-19 2019-06-19
PCT/IB2020/055653 WO2020254985A1 (en) 2019-06-19 2020-06-17 Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication

Publications (1)

Publication Number Publication Date
PH12021553180A1 true PH12021553180A1 (en) 2022-11-07

Family

ID=71738195

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2021/553180A PH12021553180A1 (en) 2019-06-19 2020-06-17 Inhibitors of human immunodeficiency virus replication

Country Status (33)

Country Link
US (2) US12129255B2 (https=)
EP (1) EP3986561B1 (https=)
JP (1) JP7628512B2 (https=)
KR (1) KR102932817B1 (https=)
CN (2) CN119039288A (https=)
AR (1) AR119174A1 (https=)
AU (1) AU2020295793B2 (https=)
BR (1) BR112021025655A2 (https=)
CL (1) CL2021003388A1 (https=)
CO (1) CO2021017479A2 (https=)
CR (1) CR20210664A (https=)
DK (1) DK3986561T3 (https=)
ES (1) ES2974541T3 (https=)
FI (1) FI3986561T3 (https=)
HR (1) HRP20240501T1 (https=)
HU (1) HUE065762T2 (https=)
IL (1) IL288750B2 (https=)
LT (1) LT3986561T (https=)
MA (1) MA56526B1 (https=)
MD (1) MD3986561T2 (https=)
MX (1) MX2021016149A (https=)
MY (1) MY206712A (https=)
PE (1) PE20220510A1 (https=)
PH (1) PH12021553180A1 (https=)
PL (1) PL3986561T3 (https=)
PT (1) PT3986561T (https=)
RS (1) RS65304B1 (https=)
SI (1) SI3986561T1 (https=)
SM (1) SMT202400153T1 (https=)
TW (1) TWI850403B (https=)
UA (1) UA128967C2 (https=)
UY (1) UY38755A (https=)
WO (1) WO2020254985A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021004593A (es) 2018-10-24 2021-06-15 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
LT3986561T (lt) 2019-06-19 2024-04-25 VIIV Healthcare UK (No.5) Limited Pirido[2,3-d]pirimidino dariniai kaip žmogaus imunodeficito viruso replikacijos inhibitoriai
WO2020254559A1 (en) 2019-06-19 2020-12-24 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US20220347174A1 (en) * 2019-10-01 2022-11-03 Viiv Healthcare Company Method for treating HIV with Cabotegravir and Rilpivirine
UY38982A (es) * 2019-12-09 2021-06-30 Viiv Healthcare Co Composiciones farmacéuticas
KR20220151655A (ko) * 2020-03-06 2022-11-15 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제
CN115397424A (zh) * 2020-04-15 2022-11-25 Viiv保健英国第五有限公司 人类免疫缺陷病毒复制的抑制剂
US20240423985A1 (en) * 2021-10-13 2024-12-26 Viiv Healthcare Uk (No.5) Limit-Ed Inhibitors of human immunodeficiency virus replication
US20250042926A1 (en) 2023-05-31 2025-02-06 Gilead Sciences, Inc. Therapeutic compounds for hiv
AR132951A1 (es) 2023-06-15 2025-08-13 Viiv Healthcare Uk No 5 Ltd Métodos e intermedios para preparar compuestos
US12594276B2 (en) 2024-02-05 2026-04-07 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030207910A1 (en) 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
IL157029A0 (en) 2001-02-02 2004-02-08 Bristol Myers Squibb Co Azaindoleoxoacetic piperazine derivatives and pharmaceutical compositions containing the same
CN102143962B (zh) * 2008-07-02 2015-03-11 爱维艾珂瑟有限公司 具有抗病毒特性的化合物
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
EP2729448B1 (en) 2011-07-06 2015-09-09 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
CA2896244C (en) 2013-01-09 2017-07-04 Gilead Sciences, Inc. 5-membered heteroaryls and their use as antiviral agents
CA2897268C (en) 2013-01-09 2018-12-04 Gilead Sciences, Inc. Therapeutic compounds for the treatment of viral infections
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
PT3186239T (pt) 2014-08-29 2019-01-10 Gilead Sciences Inc Agentes antirretrovirais
KR20230011471A (ko) 2016-08-19 2023-01-20 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물
EP3507288B1 (en) * 2016-09-02 2020-08-26 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
TW201906834A (zh) * 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
MX2021004593A (es) * 2018-10-24 2021-06-15 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
UY38559A (es) 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
LT3986561T (lt) 2019-06-19 2024-04-25 VIIV Healthcare UK (No.5) Limited Pirido[2,3-d]pirimidino dariniai kaip žmogaus imunodeficito viruso replikacijos inhibitoriai

Also Published As

Publication number Publication date
EP3986561B1 (en) 2024-02-14
JP2022537047A (ja) 2022-08-23
SI3986561T1 (sl) 2024-04-30
MA56526A (fr) 2022-04-27
BR112021025655A2 (pt) 2022-02-01
FI3986561T3 (fi) 2024-05-02
MY206712A (en) 2025-01-03
CN119039288A (zh) 2024-11-29
KR20220024608A (ko) 2022-03-03
IL288750B2 (en) 2025-04-01
UY38755A (es) 2020-11-30
SMT202400153T1 (it) 2024-05-14
AU2020295793B2 (en) 2023-07-06
PL3986561T3 (pl) 2024-06-10
EP3986561A1 (en) 2022-04-27
AU2020295793A1 (en) 2022-01-20
CR20210664A (es) 2022-01-21
HRP20240501T1 (hr) 2024-07-05
DK3986561T3 (da) 2024-03-04
TW202115055A (zh) 2021-04-16
MD3986561T2 (ro) 2024-06-30
MX2021016149A (es) 2022-05-18
UA128967C2 (uk) 2024-12-11
AR119174A1 (es) 2021-12-01
CO2021017479A2 (es) 2022-04-19
WO2020254985A1 (en) 2020-12-24
IL288750B1 (en) 2024-12-01
US12129255B2 (en) 2024-10-29
CL2021003388A1 (es) 2022-09-30
HUE065762T2 (hu) 2024-06-28
IL288750A (en) 2022-02-01
CN114245795B (zh) 2024-08-06
RS65304B1 (sr) 2024-04-30
JP7628512B2 (ja) 2025-02-10
MA56526B1 (fr) 2024-05-31
CN114245795A (zh) 2022-03-25
LT3986561T (lt) 2024-04-25
PT3986561T (pt) 2024-03-15
US20250019383A1 (en) 2025-01-16
PE20220510A1 (es) 2022-04-07
CA3143136A1 (en) 2020-12-24
KR102932817B1 (ko) 2026-03-04
TWI850403B (zh) 2024-08-01
US20210323967A1 (en) 2021-10-21
ES2974541T3 (es) 2024-06-27

Similar Documents

Publication Publication Date Title
PH12021553180A1 (en) Inhibitors of human immunodeficiency virus replication
PH12021550813A1 (en) Inhibitors of human immunodeficiency virus replication
ZA202500439B (en) Therapeutic compounds for hiv virus infection
SA519402405B1 (ar) مركبات مثبط فيروس نقص المناعة البشري
WO2019244066A3 (en) Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
ZA202107015B (en) Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
PH12020550256A1 (en) 1-benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as hiv protease inhibitors
MY174224A (en) Hepatitis b virus surface antigen inhibitor
UY37710A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
NZ741957A (en) Therapeutic compositions for treatment of human immunodeficiency virus
MX2017007814A (es) Compuesto de carbamoilpiridona policiclicos y su uso farmaceutico.
BR112017022544A2 (pt) ?composto, composição, e, método para tratamento de infecção por hiv?.
CA2998646C (en) 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof
NZ735575A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
MX2022011016A (es) Inhibidores de la replicacion del virus de inmunodeficiencia humana.
MX2022009871A (es) Compuestos tetraciclicos para tratar la infeccion por el virus de la inmunodeficiencia humana (vih).
CA3013473C (en) Methods for treatment and prophylaxis of hiv and aids
EA201170537A1 (ru) Ингибиторы вич-интегразы
MX2022012881A (es) Inhibidores de replicacion del virus de inmunodeficiencia humana.
MX2022007911A (es) Procedimiento de tratamiento de una infeccion virica usando un agonista de tlr7.
CL2024001073A1 (es) Inhibidores de la replicación del virus de inmunodeficiencia humana
MX2022007681A (es) Derivados de heteroarildihidropirimidina y metodos de tratamiento de infecciones de tipo hepatitis b.